Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $33.00.

Several research analysts have commented on AVTX shares. Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a report on Tuesday. They set a “buy” rating and a $36.00 price objective for the company. Jefferies Financial Group started coverage on Avalo Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $23.00 target price on the stock. Piper Sandler started coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Finally, BTIG Research initiated coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price for the company.

Institutional Investors Weigh In On Avalo Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. bought a new position in shares of Avalo Therapeutics during the 3rd quarter valued at approximately $9,186,000. Ikarian Capital LLC increased its position in Avalo Therapeutics by 1,673.0% during the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after acquiring an additional 915,629 shares during the last quarter. Affinity Asset Advisors LLC raised its stake in shares of Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after acquiring an additional 505,765 shares during the period. Velan Capital Investment Management LP bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth about $817,000. Finally, Geode Capital Management LLC boosted its stake in shares of Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after purchasing an additional 94,742 shares during the period. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX traded up $1.16 during midday trading on Tuesday, reaching $8.79. 121,259 shares of the company were exchanged, compared to its average volume of 210,375. The business’s fifty day moving average is $7.47 and its two-hundred day moving average is $9.13. Avalo Therapeutics has a one year low of $4.60 and a one year high of $34.46.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.